Skip to content

News

Last Chance for VIP Access to Turn Up the Heat

Last Chance for VIP Access to Turn Up the Heat

Turn Up the Heat is a foodie’s paradise, featuring treats and libations from more than 50 incredible local women chefs, mixologists, and restaurateurs. Join us on Wednesday, March 7th at the Ronald Reagan Building and International Trade Center in Washington, DC to support Ovarian Cancer Research Alliance. Until December 1st, when you buy a General … Continued

OCRFA Funded Research Identifies Mechanism Underlying Ovari...

OCRFA Funded Research Identifies Mechanism Underlying Ovarian Cancer Development

(November 22, 2017) A recent paper published in the Journal of Clinical Investigation reports that a subset of ovarian cancers reduce the expression of a critical gene involved in recycling the cells’ proteins, known as ubiquitin B (UBB). Silencing the expression of a closely related gene, also in the ubiquitin family, that performs an identical … Continued

New Research Indicates that High Grade Serous Ovarian Carci...

New Research Indicates that High Grade Serous Ovarian Carcinomas Originate in the Fallopian Tubes

(October 30, 2017) Until recently, it was thought that high-grade serous ovarian carcinomas (HGSOCs) arose from the ovarian surface epithelium, but recent data from two studies published in Nature Communications suggest that all high grade serous ovarian cancers do in fact originate in the fallopian tube. These findings have implications for ovarian cancer detection and … Continued

White Blood Cells Found in High Grade Ovarian Cancer May Po...

White Blood Cells Found in High Grade Ovarian Cancer May Point to Survival Outcomes

(October 20, 2017) An international, large scale study may have found a link between high-grade ovarian cancer and a type of white blood cell known as a tumor-infiltrating lymphocyte. Recently published in JAMA Oncology, the article from the Ovarian Tumor Tissue Analysis Consortium discussed the study, which involved about 5,500 patients, 3,196 of whom had … Continued

OCRFA Funded Study Discovers 3 Key Genes in Prevention and ...

OCRFA Funded Study Discovers 3 Key Genes in Prevention and Treatment of BRCA1 and BRCA2 Tumors

(October 19, 2017) BRCA1 and BRCA2 are among the most frequently mutated genes in ovarian cancer. Studies conducted in the past two decades have shown that BRCA1 and BRCA2 play an essential role in protecting DNA from lesions that can lead to tumor formation. However, the factors that cause DNA lesions in BRCA1- and BRCA2-deficient … Continued

Adjuvant Chemotherapy Does Not Lead to Better Survival In C...

Adjuvant Chemotherapy Does Not Lead to Better Survival In Certain Ovarian Cancers

(October 13, 2017) The National Comprehensive Cancer Network currently recommends that early stage Ovarian Clear Cell Cancers be treated with adjuvant chemotherapy, or therapy given after the primary treatment as a way to lower the risk of recurrence. However, a retrospective study published recently in Annals of Oncology found that treating stage I endometrioid epithelial … Continued

Report from 2017 AACR Special Conference Addressing Critica...

Report from 2017 AACR Special Conference Addressing Critical Questions in Ovarian Cancer Research and Treatment

(October 13, 2017) Every other year, the American Association for Cancer Research (AACR) brings together ovarian cancer researchers from around the world to share knowledge and encourage multi-disciplinary collaboration. At this year’s conference, held October 1-4 in Pittsburgh, Pennsylvania, a focus on critical questions led to energetic discussions about ways to take information from basic … Continued

OCRFA’s Response to Trump Administration’s Birth Cont...

OCRFA’s Response to Trump Administration’s Birth Control Coverage Rollback

(Oct. 11, 2017) Last week, the Trump Administration issued a regulation to immediately allow employers to deny insurance coverage for birth control on the basis of their own moral or religious objections, undermining the landmark benefit under the Affordable Care Act (ACA) that guarantees coverage for contraception without co-pays or cost-sharing. Audra Moran, President and … Continued

Studies Show that Current Chemotherapy Dosage is Still Best...

Studies Show that Current Chemotherapy Dosage is Still Best Option for Epithelial Ovarian Cancer

(September 15, 2017) Two studies just confirmed that, depending on one’s genetic background, the standard treatment for epithelial ovarian cancer is most likely the best option. The studies, conducted with two different populations, showed that, although the outcomes conflicted one another, the option that offered the best progression free survival was the one already used. … Continued

Folonari Wines Partners with OCRFA

Folonari Wines Partners with OCRFA

(September 8, 2017) Through its ongoing ‘AMORE, ITALIA, FOLONARI’ campaign, Folonari Wines has partnered this year with Ovarian Cancer Research Alliance. Joining forces with OCRFA gives Folonari a national platform to continue their fight against ovarian cancer with the ‘Time to Teal with Folonari’ campaign. Frederick Wildman and Sons will working together with its trade … Continued

The Link Between Chemotherapy Resistance and a Tumor’s BRCA...

The Link Between Chemotherapy Resistance and a Tumor’s BRCA1/2 Mutations

(September 5, 2017) Researchers at the University of Pennsylvania recently uncovered a link between one’s resistance to common types of chemotherapy and one’s tumor BRCA1/2 mutation status. More specifically, they looked at both copies of the BRCA genes, one copy given by each parent. Until recently, it had been assumed that mutated BRCA gene left … Continued

Share Your #OvarianStory to Raise Awareness

Share Your #OvarianStory to Raise Awareness

Every 23 minutes another woman is diagnosed with ovarian cancer. All of them have a story. This September, we’re inviting you to share your #OvarianStory. Help raise awareness of ovarian cancer, from the first often-missed symptoms, to diagnosis and beyond. By speaking out, you can help other women and you can shine a spotlight on … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.